TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23063027
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily insulin dose
Study: 23063027
Drug: Type of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type of insulin regimen (basal/bolus versus SSI)
Study: 19544136
Drug: Daily reports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily reports of vaginal sex
Study: 17179056
Drug: Black cohosh,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh, 160 mg daily
Study: 17179056
Drug: Multibotanical with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multibotanical with black cohosh, 200 mg daily, and 9 other ingredients
Study: 17179056
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen, 0.625 mg daily, with or without medroxyprogesterone acetate, 2.5 mg daily
Study: 14529055
Drug: Zolmitriptan 2.5
Normalized name: zolmitriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 2.5 mg orally disintegrating tablet (ODT)
Study: 6699312
Drug: Aminophylline therapy
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline therapy added to metaproterenol sulfate and beclomethasone dipropionate aerosol therapy
Study: 6699312
Drug: Aminophylline therapy
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline therapy added to metaproterenol sulfate aerosol
Study: 6699312
Drug: Aminophylline therapy
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline therapy
Study: 31056291
Drug: Gentamicin 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 240 mg
Study: 22677092
Drug: Nurse-led self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led self-help treatment plus usual care
Study: 19818588
Drug: Rose-hip powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rose-hip powder 5g daily
Study: 12419472
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 microg)
Study: 12621381
Drug: Indinavir 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 1000 mg every 8 hours plus rifabutin 150 mg daily
Study: 12621381
Drug: Rifabutin 150
Normalized name: rifabutin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin 150 mg daily with indinavir
Study: 12621381
Drug: Rifabutin 300
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg daily alone
Study: 8559498
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 5 mg/kg
Study: 8559498
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 4 mg/kg
Study: 21458107
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 3 mg/kg
Study: 8559498
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) 2 mg/kg
Study: 2387651
Drug: PPA 15
Normalized name: APAP 200/ASA 230/PPA 15MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA 15 mg
Study: 30001727
Drug: Lotilaner (Credelio™)
Normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner (Credelio™) administered orally at a dose of 6 mg/kg
Study: 24892113
Drug: NobelActive implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: NobelActive implants (Nobel Biocare)
Study: 24892113
Drug: NobelSpeedy Groovy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NobelSpeedy Groovy implants (Nobel Biocare)
Study: 21512834
Drug: Parent-mediated communication-focused
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-mediated communication-focused treatment for autism
Study: 20079528
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose followed by 90 mg twice a day)
Study: 20079528
Drug: Clopidogrel (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300-600 mg loading dose or continuation with maintenance dose followed by 75 mg per day)
Study: 18003434
Drug: Alprazolam (different
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (different doses)
Study: 15942259
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg estradiol valerate)
Study: 15942259
Drug: Estradiol plus
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol plus progesterone (100 mg micronized progesterone)
Study: 9915533
Drug: Prazosin 1
Normalized name: prazosin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 1 mg orally 12 hours before surgery, just before surgery, and 12 and 24 hours after surgery
Study: 8740302
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (1 g/m2 per day divided into two equal doses)
Study: 29443788
Drug: Repeated-doses RSB
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated-doses RSB analgesia
Study: 26721259
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg/day for 21 days
Study: 23088350
Drug: α1 noradrenergic
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: α1 noradrenergic blockers + α2 noradrenergic agonists
Study: 23088350
Drug: voltage-sensitive sodium
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: voltage-sensitive sodium channel anticonvulsants
Study: 23088350
Drug: α2δ voltage-sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: α2δ voltage-sensitive calcium channel blockers
Study: 22265143
Drug: Riboflavin 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 0.1% (w/v) eyedrops - 20% dextran solution for 1 month
Study: 17413684
Drug: Etravirine 400
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine 400 mg twice a day
Study: 17413684
Drug: Etravirine 800
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine 800 mg twice a day
Study: 17413684
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (optimized regimens of at least three antiretroviral agents)
Study: 15752409
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 microg added to 18 mg hyperbaric ropivacaine
Study: 15752409
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (3 ml of 18 mg hyperbaric ropivacaine + 0.5 ml saline)
Study: 11307032
Drug: Step-down therapy
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down therapy with 1200 microg/day of BDP for 4 weeks with short-term oral steroid (prednisolone, 0.5 mg/day for 1 week)
Study: 11307032
Drug: Step-down therapy
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down therapy with 1200 microg/day of BDP for 4 weeks without oral steroids
Study: 11307032
Drug: Step-up therapy
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up therapy with 400 microg/day of BDP for 4 weeks, then 800 microg/day for another 4 weeks
Study: 11307032
Drug: Step-down therapy
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down therapy with 1200 microg/day of BDP for 4 weeks with short-term oral steroid
Study: 4099843
Drug: Preseasonal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preseasonal immunization with large doses of ragweed pollen extract
Study: 31119479
Drug: Imatinib (Gleevec;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (Gleevec; STI571) at a fixed dose of 600 mg/D
Study: 31119479
Drug: Imatinib (Gleevec;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (Gleevec; STI571) at 600 mg/D
Study: 24288395
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with 16 mg azelnidipine (O/A group)
Study: 24288395
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with 1 mg indapamide (O/D group)
Study: 20085177
Drug: Keishinieppiittokaryojutsubu (KER;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keishinieppiittokaryojutsubu (KER; decoction) in combination with oral methotrexate (MTX)
Study: 7733128
Drug: i.v. thiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. thiamine 200 mg/d
Study: 6798734
Drug: Tocainide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide (oral analogue of lidocaine)
Study: 29131820
Drug: Single praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single praziquantel treatment
Study: 29131820
Drug: Two praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two praziquantel treatments
Study: 25835230
Drug: Chito group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chito group (3 g/day chitosan)
Study: 25835230
Drug: Chito-vita group
Normalized name: Vita-Respa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chito-vita group (3 g/day chitosan plus 2 g/day L-ascorbic acid)
Study: 22067628
Drug: Haloperidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5 mg intravenous bolus injection followed by continuous infusion at a rate of 0.1 mg/h for 12 hrs; n = 229)
Study: 17217318
Drug: 17beta‐estradiol 2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 2mg and norethisterone acetate 1mg (Cliane) daily for 6 months
Study: 17217318
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet daily for 6 months
Study: 12355489
Drug: Daily diaries
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily diaries documenting frequency and duration of RP attacks
Study: 10206791
Drug: Td-eIPV (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td-eIPV (single dose)
Study: 10206791
Drug: Td-eIPV (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td-eIPV (two doses)
Study: 649013
Drug: Dolo Mobilat
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolo Mobilat film tablets
Study: 23020939
Drug: Intravenous flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous flurbiprofen axetil (50 mg)
Study: 23020939
Drug: Intramuscular tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tramadol (100 mg)
Study: 18772641
Drug: ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 800 mg 3 times daily
Study: 16202199
Drug: Unrestored teeth
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unrestored teeth (MOD cavity preparation)
Study: 7496880
Drug: Information or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information or utilization management intervention (e.g., patients or physician education, telephone follow‐up, patient or physician reminders, home care services)
Study: 378350
Drug: Total body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total body irradiation (TBI), 100 rads in 10 fractions over 12 days plus combination chemotherapy (CVP or C-MOPP)
Study: 378350
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CVP or C-MOPP) alone
Study: 28287044
Drug: Teriparatide (Forsteo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (Forsteo, 20 μg daily for 2 months postoperatively)
Study: 21756808
Drug: Imatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib plus Hyper-CVAD chemotherapy
Study: 12938838
Drug: Stainless steel
Normalized name: stainless steel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stainless steel wire with a buccal offset of 1 mm, reactivated every four weeks.
Study: 10184318
Drug: Levodropropizine (LD)
DrugBank: Levodropropizine (DB12472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodropropizine (LD) 60 mg t.i.d. as oral drops for 8 days
Study: 2900919
Drug: rt-PA 100
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA 100 mg plus heparin
Study: 29490105
Drug: Daily Breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Breakfast Consumption (DBC)
Study: 20133925
Drug: Oxygen-conserving devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-conserving devices at 2 L O(2)/min
Study: 16466167
Drug: Bushen Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Granule (BSG) combined with Marine Injection (MI)
Study: 12502940
Drug: Moisturizing agent
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizing agent usage
Study: 1958439
Drug: Betahistine 72
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 72 mg three times daily
Study: 1958439
Drug: Prochlorperazine 5
Normalized name: prochlorperazine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 5 mg three times daily
Study: 28735928
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg (active reference)
Study: 25720711
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy and rehabilitation training
Study: 25720711
Drug: Conventional therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy, rehabilitation training and botulinum toxin type A injection
Study: 25720711
Drug: AFO plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFO plus conventional therapy and rehabilitation training
Study: 22081618
Drug: Mate tea
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mate tea consumption (330 mL, 3 times a day for 60 days)
Study: 19843808
Drug: Naloxone group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone group (34 mL lidocaine 1.5% with 100 ng naloxone)
Study: 19843808
Drug: Naloxone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone + Fentanyl group (34 mL lidocaine 1.5% with 100 microg fentanyl and 100 ng naloxone)
Study: 19843808
Drug: Fentanyl group
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl group (34 mL lidocaine 1.5% with 100 microg fentanyl)
Study: 19843808
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (34 mL lidocaine 1.5% with isotonic saline)
Study: 11517140
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg intravenously at the end of surgery and 8 mg in PCA morphine solution
Study: 11517140
Drug: Morphine via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine via PCA syringe
Study: 2973300
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with rt-PA immediately followed by transluminal coronary angioplasty (group 1, n = 183)
Study: 28647541
Drug: Response tailored
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response tailored duration of dual sofosbuvir/daclatasvir treatment (8 or 12 weeks based on vRVR)
Study: 28647541
Drug: Fixed 12
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed 12 weeks duration of dual sofosbuvir/daclatasvir treatment
Study: 25280085
Drug: Fostamatinib (R788)
Normalized name: fostamatinib
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib (R788) 100 mg BID
Study: 23459567
Drug: Alemtuzumab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (12 mg or 24 mg)
Study: 16871129
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 20 mg/day
Study: 16871129
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 40 mg/day
Study: 16871129
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 60 mg/day
Study: 16871129
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR (all doses)
Study: 14668006
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of mifepristone every 2 weeks for 24 weeks
Study: 9395376
Drug: Interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-alpha) therapy, 3 MU, 3 times a week for 6 months
Study: 9395376
Drug: Interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-alpha) therapy, 3 MU, 3 times a week for 12 months
Study: 8236464
Drug: Proguanil daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil daily (PROG)
Study: 8236464
Drug: Chloroquine once
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine once weekly (CQ)
Study: 8236464
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Chloroquine and Proguanil (CQ+PROG)
Study: 29540410
Drug: Patella mobilisation
Normalized name: Blatella germanica
DrugBank: Blatella germanica (DB10418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patella mobilisation therapy (PMT) with three manual mobilisation sessions and home-based vastus medialis oblique muscle exercise at 2-month intervals
Study: 22568118
Drug: TAU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU plus bBTi (4 weekly 1-hour individual sessions)
Study: 17233546
Drug: Osteoporosis medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoporosis medications (e.g., Bisphosphonates)
Study: 17233546
Drug: Strategies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategies to increase adherence (e.g., reducing administration frequency, monitoring patients, providing instructions)
Study: 17233546
Drug: Non-adherence factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adherence factors (e.g., adverse effects, pain, uncertainty about BMD test results)
Study: 240481
Drug: Practolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (200 mg twice daily)
Study: 31810418
Drug: Quadrivalent influenza
Normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent influenza vaccine (QIV) in thiomersal-containing multi-dose vial (MDV) format
Study: 30467686
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Clopidogrel + Cilostazol
Study: 25925203
Drug: IV amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV amino acid therapy (up to 100 g daily)
Study: 23948391
Drug: overnight storage
Approvals — FDA: no, EMA: no, PMDA: no
Description: overnight storage with alkaline peroxide-based cleansing tablet
Study: 15451900
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (premeal inhaled insulin plus a bedtime dose of Ultralente)
Study: 15451900
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (at least two daily injections of mixed regular/NPH insulin)
Study: 9229982
Drug: Minimal-flow anaesthesia
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-flow anaesthesia with desflurane (0.5 l/min fresh gas flow)
Study: 9229982
Drug: Low-flow anaesthesia
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow anaesthesia with desflurane (1.0 l/min fresh gas flow)
Study: 9229982
Drug: High-flow phase
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow phase with desflurane (4.4 l/min fresh gas flow)
Study: 3524549
Drug: Prostaglandin F2
Normalized name: Prostaglandin F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2 alpha in Tylose gel
Study: 24453500
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency (PRF) treatment at 42°C for 120 seconds to the dorsal root ganglion (DRG)
Study: 12190752
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.2‐0.4 micro g.kg‐1.min‐1)
Study: 12190752
Drug: Fentanyl bolus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl bolus (3 micro g.kg‐1) + propofol infusion (2 mg.kg‐1.h‐1)
Study: 6211167
Drug: Atropine methonitrate
Normalized name: Atropine methonitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine methonitrate (2 mg) as a wet aerosol
Study: 6211167
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium bromide and terbutaline
Study: 6211167
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide and terbutaline combination
Study: 23813620
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 mg single dose